Roth Capital 'Encouraged' by Notice of Intent in Cytori's (CYTX) Contract with BARDA
Tweet Send to a Friend
Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $10 following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
